JPRN-UMIN000006322招募中2 期
A phase II study of Bevacizumab and Docetaxel for elderly patients advanced Non-Small Cell Lung Cancer - A phase II study of Bevacizumab and Docetaxel for elderly patients with NSCLC
niversity hospital, Hirosaki University School of Medicine Cardiology,respiratory medicine and nephrology0 个研究点目标入组 30 人开始时间: 2011年9月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Subjects with interstitial pneumonia or pulmonary fibrosis. 2)Uncontrolled systematic disease 3)Uncontrolled active infection 4)No other active malignancies 5)Concurrent use of steroid therapy 6)Subjects with brain metastases 7)Uncontrolled pleural effusion and ascites 8)have had or require continuous oral administration of hemostat/have had or require injectable administration of hemostat 9)Pregnant patients 10)Have a bleeding diathesis 11)Tumor invasion to major vessels 12)Cavity in tumor 13)History of uncontrolled gastroduodenal ulcer 14)Uncontrolled hypertension 15)Symptomatic heart failure,unstable angina, uncontrolled arrhythmia, myocardial infarction within 1 year 16)Symptomatic cerebrovasucular disease 17)Any other reason that,in the opinion of the investugator precludes the subject from participating in the study.
研究者
相似试验
招募中
2 期
A phase II study of Bevacizumab plus Docetaxel for advanced large cell neuroendocrine carcinoma (LCNEC) with previously treated with platinum based chemotherapyarge cell neuroendocrine carcinoma (LCNEC)JPRN-UMIN000011713Toho University Omori Medical Center19
已完成
2 期
A phase II study of Docetaxel with Bevacizumab for EGFR mutation negative previously treated non-squamous non-small cell lung canceron-Squamous Non-Small Cell Lung CancerJPRN-UMIN000006532ihon University School of Medicine30
已完成
不适用
A phase II study of Docetaxel with Bevacizumab for previously treated non-squamous non-small cell lung cancer.non-squamous non-small cell lung cancer.JPRN-UMIN000008687First Department of Internal Medicine,25
进行中（未招募）
不适用
A phase II study of Bevacizumab with Docetaxel and Capecitabine in the neoadjuvant setting for breast cancer patientsneoadjuvant treatment of patients with primary breast cancer and no distant metastasesEUCTR2005-005883-10-ATRoche Austria GmbH10
已完成
1 期
Phase I/II study of Docetaxel with Bevacizumab for refractory and geriatric non-squamous non-small cell lung canceron-Squamous Non-Small Cell Lung CancerJPRN-UMIN000006152Chiba Tokushukai Hospital20